Background
==========

The population epidemiology of diabetes mellitus is of public health interest from several perspectives. Diabetes has severe costs for afflicted patients, as it is a chronic lifelong disease characterized by excess mortality \[[@B1]\] and high comorbidity with cardiovascular disease, nephropathy and eye complications as prominent examples \[[@B2]\]. Diabetes has a high impact on general populations, in particular in Western societies: The prevalence increases with age and reaches a level of about 10% at the age of 60 years and above in most populations \[[@B1]\]. Diabetes prevalence has been found to increase in all age groups during the last 20 years, and WHO has estimated that the number of diabetics in the world will more than double within the next 25 years from about 170 million in 2000 to about 366 million in year 2030 \[[@B3]\]. This increase of about 3.1% per year in prevalence has been claimed to fulfill the criteria for an epidemic, particularly of type 2 diabetes \[[@B4],[@B5]\]. Others have claimed that an increase in prevalence alone cannot be taken as proof of an ongoing epidemic \[[@B6]\]. Also, prevention of diabetes (in particular type II) has attracted much attention with focus on the relation between lifestyle and risk of becoming a diabetic, and several countries have set up large scale prevention programs. From a medical point of view, the secondary prophylaxis is of high interest with focus on improving life quality and survival with diabetes through health initiatives ranging from motivational intervention, monitoring of disease, to new pharmaceutical treatments.

At the heart of these perspectives is the need to obtain valid and current estimates on trends in diabetes incidence, prevalence and mortality. Such estimates are, however, typically costly to obtain on a general population level, and are hence often missing. In this context, it has been suggested that pharmacoepidemiological databases could be used to study the dynamics of the diabetes epidemiology for large, well-defined populations, even when the databases only contain information on filled prescriptions \[[@B7]\]. A prime advantage of using pharmacoepidemiological databases for such epidemiological descriptions is obviously that the data are readily available. But, although other studies have shown that diabetes prevalence may be reliably estimated from total consumption data \[[@B8]-[@B10]\], the use of individual claims data for a more detailed analysis of trends in incidence, prevalence and mortality has so far received less attention. Such an approach is not without its challenges, since both date of onset as well as true, current disease status are not recorded in this type of pharmacoepidemiological databases. Misclassification is thus a potential problem, and the type of potential bias introduced by different strategies for determining treatment status at any given point in time must be carefully considered. Indeed, intuitively attractive approaches may introduce strong biases when studying calendar time trends, as discussed below. Although we update and extend previously published results on the epidemiology of diabetes in the Funen population \[[@B7]\], the primary objective of this paper is methodological. First, we investigate the impact of different choices of run-in periods, as this is a crucial methodological issue in many pharmacoepidemiological studies. Secondly, we study the relative contributions of current trends in incidence and mortality to the concurrent, observed rise in diabetes prevalence, ie. we focus on the question: Can prevalence rise while contemporary incidence and mortality rates remain constant?

Methods
=======

Odense Pharmaco-Epidemiologic Database (OPED) was used as data source. OPED contains information on all redemptions of subsidized and prescribed drugs at community pharmacies in the county of Fyn, Denmark \[[@B11]\] since 1992. It is a copy of the exhaustive electronic register maintained for administering all subsidies to pharmacies as well as prescribing physicians in the county. Information on the drug is entered directly into the electronic register when a prescription is processed and dispensed -- which yields very high validity \[[@B12]\] -- and in accordance with the Anatomical Therapeutical Chemical (ATC) classification system \[[@B13]\]. All anti-diabetic drugs are characterized by the first three characters being A10, insulin by A10A, oral anti-diabetics by A10B.

OPED contains information on birth date, gender, migration and death for all subjects living within the county in the period January 1, 1992 to December 31, 2003 in accordance with the Danish Central Person Register. All records allow unique tracking of individuals by means of the nationwide Civil Registration Number.

For each individual we determined presence and treatment status with respect to use of anti-diabetic medications on January 1 of each calendar year (the index date). We defined treatment status based on a previous run-in period\'s recordings of anti-diabetic drug dispensing, ie. if a subject had at least one prescription within the run-in period, the person was considered treated at the index date. Consequently, for each calendar year we excluded all who immigrated into Fyn during the run-in period, since we could not determine treatment status with certainty for immigrants without an observed redemption.

For those present at the index date and with a sufficient run-in period, we computed annual counts of these entities: prevalence (**P**), incidence (**I**), treatment cessation (**C**), deaths among all non-prevalents (**D**~**0**~), deaths among prevalents (**D**~**1**~), and deaths among incidents (**D**~Inc~). An individual was considered prevalent on the index date if a redemption was observed in the associated run-in period. Incidence was defined as the number of subjects having a redemption in the year of interest, but not in the run-in period. Mortality counts were number of deaths in the year of interest stratified on prevalence status at the index date. Among those prevalent at the index date we defined treatment cessation as having been observed for a period which exceeded the length of the run-in period without any new redemptions and which overlapped the index date. In a sub-analysis of the annual transitions between treatment states (treated or not), we further subdivided the number of subjects who had discontinued treatment into two groups: Those who re-initiated treatment within the calendar year, and those who did not.

For incidence and mortality among non-prevalents and prevalents, respectively, we computed rates based on counts and time at risk for the event in question. Time at risk was defined as time from index date to either event or censoring by migration, death, or end of year, whichever was first. Relative mortalities were obtained by comparing mortality rates among prevalents to rates among non-prevalents.

In the sub-analyses of insulin and oral anti-diabetic medications, only redemptions of the specific type were considered; for example, all redemptions of oral anti-diabetic agents were ignored when restricting the analysis to insulin.

Choosing the length of the run-in period is crucial in this study, as in most pharmacoepidemiological studies, since rates of exclusion must be balanced with misclassification. For the fixed run-in periods we did two separate analyses with lengths of one and two years, respectively. The length of one year allows comparison with previously published results \[[@B7]\], but we found it to be inadequate for accommodating a change in the Danish subsidy system taking place in 2000. We thus report on the effects of this change and provide estimates based on a two years run-in period, as these are unaffected by the switch. For illustrative purposes we also present estimates based on increasing the run-in period with calendar time, although these are invalid as they introduce time-dependent misclassification.

As trends in observed incidence of treatment initiation both depends on the true trend in disease incidence as well as trends in detection and tendency to initiate pharmacological treatment, we conducted a sensitivity analysis. Within each year we assume that there is an unknown incidence proportion with an annual trend *ρ*. Further assume that there is a detection probability *π*~*Y*~, ie. of transition from undiagnosed to becoming diagnosed and initiating pharmacological treatment given that one becomes diabetic. We assumed that *π*~1994~was 60%. Note that results of the sensitivity analysis with respect to trends are virtually insensitive to the actual level of detection, so this choice is not crucial. For changes in this probability we assumed that they were in the range from a decline of 10 percentage points to an increase of 20 percentage points from 1994 to 2003, ie. that detection proportions in 2003 ranged from 50% to 80%. This corresponds to annual changes of -2.0% to 3.2% in detection proportions, ie. a ratio *θ*of 0.980 to 1.032 between subsequent years. The annual trend *ρ*in true incidence can now be related to the observed trend *φ*in incidence of treatment by the following formula

$\rho = \frac{\varphi}{\theta}\text{~~~~~}\left( 1 \right)$

We present graphs showing the relationship between trends in true incidence and the observed trend in treatment incidence when detection proportions vary.

We finally investigated the extent to which the rise in prevalence could be explained by concurrent trends in incidence, mortality among treated and cessation rates, respectively. We did so by comparing the observed annual prevalences to projections based on fixing age-specific rates of incidence, mortality and cessation among treated to their values in 1994. Alternatively, incidence alone was fixed to its level in 1994 to study the isolated impact of a trend in incidence.

Statistical analysis
--------------------

Annual incidence, prevalence and mortality rates were determined within four age categories stratified by sex. Annual trend estimates were obtained from regression analysis with year and age categories (cut points at 15, 25, \..., 85) as covariates stratified on gender. Logistic regression was employed for analyzing prevalence, Poisson regression for incidence and mortality rates. In the analyses of prevalence and incidence, correlations among individual\'s outcomes in subsequent years where allowed for by using robust standard errors \[[@B14],[@B15]\]. For prevalence the trend was estimated as a linear trend on the log-odds-ratio scale, whereas trends in both incidence and mortality were estimated as linear trends on a log-rate-ratio scale. Cessation rates were not analyzed for trends as they are not of primary interest and in any case estimates would be based on small numbers. Estimates of age-adjusted annual trends with 95%-confidence intervals are given as odds-ratios and rate-ratios. All analyses were performed in Stata 8 \[[@B16]\].

Results
=======

Basic characteristics of the studied population are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} using a two year run-in period. Population size is almost constant with only a slight increase while the age-composition changes with an increase in the middle-aged group (40--64 years) and among children (\<15), and a decline among younger adults (15--39 years). For both sexes, and in all age-groups, prevalence increases, most distinctly among middle-aged, as does incidence, with males aged 15--39 years as the only exception. The total number of deaths among untreated across all age groups declines over the study period, in particular among males above age 65. Mortality among treated increases in absolute numbers, but declines relatively when compared to the concurrent increase in prevalence. A graphical presentation of relative measures is given in Figure [1](#F1){ref-type="fig"}.

###### 

Characteristics of source population

  **Females**   Age                                                                                                                                                             
  ------------- -------- ---------- ---------- -------- -------- -------- ----- ---- -------- -------- -------- ------- ----- -------- -------- -------- ------- ----- -------- --------
                \<15     15 -- 39   40 -- 64   65 \>                                                                                                                            
                                                                                                                                                                                
  Year          Size     P          I          *D*~1~   *D*~0~   Size     P     I    *D*~1~   *D*~0~   Size     P       I     *D*~1~   *D*~0~   Size     P       I     *D*~1~   *D*~0~
                                                                                                                                                                                
  1994          34,514   10         0          0        8        73,456   339   43   0        39       71,305   967     147   12       318      45,884   2,049   226   197      2,081
  1995          34,806   6          3          0        7        72,593   343   33   2        34       72,133   1,046   146   18       313      45,862   2,069   217   234      2,156
  1996          35,398   8          20         0        8        71,502   338   46   0        39       73,031   1,099   163   11       325      45,702   2,056   271   196      2,133
  1997          35,985   23         11         0        6        70,541   345   27   0        33       73,798   1,149   154   16       311      45,625   2,145   226   219      2,121
  1998          36,919   32         7          0        6        69,832   323   29   2        23       74,896   1,221   139   16       314      45,439   2,185   254   211      2,043
  1999          37,260   35         9          0        6        69,089   303   39   0        22       75,568   1,234   178   20       323      45,472   2,264   260   206      2,171
  2000          37,627   38         8          0        7        68,040   320   41   1        28       76,436   1,293   205   23       310      45,407   2,346   267   190      2,078
  2001          38,124   40         10         0        7        66,874   330   49   1        24       77,218   1,412   213   27       308      45,392   2,430   275   187      2,057
  2002          38,335   43         12         0        6        66,007   341   45   0        36       77,832   1,500   226   22       276      45,571   2,562   298   219      2,207
  2003          38,420   48         11         0        4        65,147   360   78   2        27       78,712   1,620   253   26       307      45,561   2,656   314   221      2,025
                                                                                                                                                                                
  **Males**     Age                                                                                                                                                             
                                                                                                                                                                                
                \<15     15 -- 39   40 -- 64   65 \>                                                                                                                            
                                                                                                                                                                                
  Year          Size     P          I          *D*~1~   *D*~0~   Size     P     I    *D*~1~   *D*~0~   Size     P       I     *D*~1~   *D*~0~   Size     P       I     *D*~1~   *D*~0~
                                                                                                                                                                                
  1994          36,066   12         2          0        12       77,830   408   49   1        83       71,598   1,424   227   52       478      33,454   1,658   241   203      1,974
  1995          36,486   9          3          0        10       76,891   419   45   2        102      72,555   1,525   212   39       451      33,364   1,714   209   189      2,030
  1996          37,173   7          26         0        5        75,486   415   55   6        82       73,548   1,597   250   28       448      33,209   1,761   232   197      2,057
  1997          37,857   31         5          0        9        74,528   423   36   2        87       74,466   1,739   248   37       455      32,994   1,811   215   203      1,866
  1998          38,839   36         3          0        13       73,694   425   40   2        65       75,668   1,826   292   44       471      32,997   1,887   236   192      1,857
  1999          39,368   36         8          0        9        72,550   430   42   6        86       76,434   1,956   286   44       455      33,087   1,974   223   213      1,890
  2000          39,741   41         14         0        12       71,316   422   41   3        67       77,268   2,103   315   52       463      33,137   2,014   253   184      1,780
  2001          39,882   46         13         1        12       70,321   436   51   1        47       77,965   2,227   340   48       444      33,425   2,158   237   226      1,804
  2002          40,034   49         11         0        12       69,106   455   64   2        67       78,888   2,414   389   59       477      33,655   2,213   270   228      1,723
  2003          40,093   47         6          0        10       68,146   466   43   3        62       79,606   2,583   401   59       469      34,163   2,357   333   230      1,657

Size of population, prevalence, incidence, and mortality with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994--2003. **Size**is the size of the population on January 1, 1993--2003, where subjects migrating into the capture area in the preceding year are ignored. **P**is the count of prevalent subjects at January 1 of the given year. **I**is the count of incident subjects during the calendar year. **D**~**1**~is the count of deaths during the year among subjects prevalent at the beginning of the year. **D**~**0**~are deaths among non-prevalents in the year.

###### 

Characteristics of source population (totals for Table 1)

         Females   Males                                                     
  ------ --------- ------- ----- ----- ------- --------- ------- ----- ----- -------
  1994   225,159   3,365   416   209   2,446   218,948   3,502   519   256   2,547
  1995   225,394   3,464   399   254   2,510   219,296   3,667   469   230   2,593
  1996   225,633   3,501   500   207   2,505   219,416   3,780   563   231   2,592
  1997   225,949   3,662   418   235   2,471   219,845   4,004   504   242   2,417
  1998   227,086   3,761   429   229   2,386   221,198   4,174   571   238   2,406
  1999   227,389   3,836   486   226   2,522   221,439   4,396   559   263   2,440
  2000   227,510   3,997   521   214   2,423   221,462   4,580   623   239   2,322
  2001   227,608   4,212   547   215   2,396   221,593   4,867   641   276   2,307
  2002   227,745   4,446   581   241   2,525   221,683   5,131   734   289   2,279
  2003   227,840   4,684   656   249   2,363   222,008   5,453   783   292   2,198

Total size of population, prevalence, incidence, and mortality with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994--2003, cf. Table 1. **Size**is the size of the population on January 1, 1993--2003, where subjects migrating into the capture area in the preceding year are ignored. **P**is the count of prevalent subjects at January 1 of the given year. **I**is the count of incident subjects during the calendar year. **D**~**1**~is the count of deaths during the year among subjects prevalent at the beginning of the year. **D**~**0**~are deaths among non-prevalents in the year.

![Prevalence, incidence and mortality estimates stratified by gender and age, Fyn County, Denmark, 1994--2003. Line-styles indicate age-categories in years: --- 0--14, - - 15--39, \... 40--64, -·- 65+.](1478-7954-5-2-1){#F1}

Careful inspection of Table [2](#T2){ref-type="table"} reveals that book-keeping with respect to prevalence does not tally in the following sense: The prevalence of a given year does not correspond to the prevalence plus incidence minus deaths among treated of the previous year. What is missing is the count of apparent treatment cessations. In Table [3](#T3){ref-type="table"} the book-keeping is carried out including the annual number of treatment cessations and correcting the number of deaths among the prevalents accordingly. The final column of Table [3](#T3){ref-type="table"} shows that the discrepancy between the predicted prevalence according to this book-keeping principle and the actually recorded prevalence is small. The difference is due to censoring induced by migration, since the cohort is open.

###### 

Book-keeping for size of total prevalent population

  Gender    Year   P      I     C~**NI**~   C~**I**~   *D*~1~   *D*~Inc~   Diff
  --------- ------ ------ ----- ----------- ---------- -------- ---------- ------
  Females   1994   3365   416   107         11         207      18         
            1995   3464   399   123         10         248      12         -3
            1996   3501   500   109         12         206      22         9
            1997   3662   418   94          7          230      23         -24
            1998   3761   429   114         9          225      19         5
            1999   3836   486   91          11         223      14         -15
            2000   3997   521   83          9          209      19         -11
            2001   4212   547   92          8          213      15         -14
            2002   4446   581   96          21         237      20         -8
            2003   4684   656   84          15         244      24         -10
                                                                           
  Males     1994   3502   519   94          5          254      23         
            1995   3667   469   109         6          226      18         -6
            1996   3780   563   96          12         228      31         -21
            1997   4004   504   106         7          239      18         -15
            1998   4174   571   105         12         235      26         11
            1999   4396   559   97          11         261      22         -9
            2000   4580   623   80          17         235      26         -17
            2001   4867   641   96          18         274      21         -21
            2002   5131   734   97          25         288      27         -7
            2003   5453   783   111         15         283      39         -27

Bookkeeping for size of total prevalent population with respect to anti-diabetic treatment, Fyn County, Denmark, 1994--2003. **P**is prevalence on Jan 1 of the given year, **I**is number of incident subjects, **C**~**NI**~is number of persons having discontinued treatment without re-initiation in the given year, **C**~**I**~is number of persons having discontinued treatment who re-initiated treatment within the given year, *D*~1~is number of deaths among treated, and *D*~Inc~is number of incident subjects dying before the end of the year. **Diff**for year *Y*is *P*~*Y*~- (*P*~*Y*-1~+ *I*~*Y*-1~- *C*~**NI**,\ *Y*-1~- *D*~1,*Y*-1~- *D*~Inc,\ *Y*-1~), ie. difference between observed and predicted prevalence. Note, that **C**~**I**~does not enter into the computation of **Diff**since these subjects both leave and re-enter the prevalent pool of subjects in the same year.

Table [4](#T4){ref-type="table"} gives estimates of age- and sex-adjusted trends. Both prevalence and incidence trend estimates are positive and statistically significant, regardless of gender, anti-diabetic drug type, and length of run-in. Mortality declines among treated (except for males with respect to insulin when using a two year run-in period) over the study period, and notably also relative to the non-treated population.

###### 

Trend estimates for incidence, prevalence, and mortality with respect to treatment with anti-diabetic agents

  Run-in     Treatment           Gender   Prevalence   Incidence      Mortality among treated   Relative Mortality                                  
  ---------- ------------------- -------- ------------ -------------- ------------------------- -------------------- ------- -------------- ------- --------------
  One year   All anti-diabetic   F        1.036        1.032, 1.040   1.045                     1.035, 1.055         0.973   0.959, 0.987   0.991   0.986, 0.995
                                 M        1.044        1.040, 1.048   1.045                     1.036, 1.054         0.974   0.961, 0.987   0.977   0.973, 0.982
             Insulin             F        1.036        1.030, 1.043   1.048                     1.033, 1.064         0.977   0.955, 1.000   0.990   0.986, 0.994
                                 M        1.045        1.039, 1.050   1.067                     1.053, 1.082         1.000   0.976, 1.023   0.977   0.973, 0.981
             Oral antidiab.      F        1.045        1.039, 1.051   1.052                     1.042, 1.059         0.969   0.953, 0.986   0.992   0.987, 0.996
                                 M        1.052        1.046, 1.058   1.049                     1.040, 1.058         0.959   0.943, 0.974   0.979   0.975, 0.984
                                                                                                                                                    
  Two year   All anti-diabetic   F        1.035        1.031, 1.039   1.048                     1.038, 1.058         0.972   0.959, 0.986   0.990   0.986, 0.995
                                 M        1.045        1.040, 1.049   1.045                     1.035, 1.054         0.978   0.965, 0.991   0.978   0.974, 0.982
             Insulin             F        1.034        1.028, 1.040   1.049                     1.033, 1.065         0.970   0.949, 0.992   0.990   0.986, 0.994
                                 M        1.045        1.040, 1.051   1.065                     1.050, 1.080         1.005   0.983, 1.028   0.977   0.973, 0.982
             Oral antidiab.      F        1.043        1.037, 1.049   1.055                     1.045, 1.066         0.970   0.954, 0.987   0.991   0.987, 0.995
                                 M        1.052        1.046, 1.058   1.050                     1.040, 1.060         0.964   0.949, 0.979   0.980   0.976, 0.984
                                                                                                                                                    
  Variable   All anti-diabetic   F        1.046        1.042, 1.050   1.032                     1.023, 1.041         0.974   0.962, 0.985   0.991   0.987, 0.995
                                 M        1.053        1.049, 1.057   1.028                     1.020, 1.036         0.973   0.962, 0.984   0.979   0.975, 0.982

Estimated age-adjusted, annual trends with 95%-confidence intervals for different categories of anti-diabetic drugs and with different lengths of run-in periods, Fyn County, Denmark, 1992--2003. For prevalence the trend estimate is given as an odds-ratio based on logistic regression, whereas the remaining estimates are rate-ratios based on Poisson regression. The start of the study period depends on the length of run-in period used.

Methodological considerations I: Length of run-in
-------------------------------------------------

Table [5](#T5){ref-type="table"} shows the annual count of patients defined as having discontinued treatment based on a gap of either one year or two years between last redemption in the run-in period and first redemption in the following year. Using a gap of one year leads to a peak in 2001 reflecting a change in reimbursement policy in 2000, so apparently some have stockpiled in early 2000 followed by a longer period without redemptions. This effect is smoothed out by using a gap of two years, i.e. the two year run-in period defines treatment status without obvious time-dependent misclassification.

As seen from Table [4](#T4){ref-type="table"} there is, however, virtually no difference in trend estimates of prevalence, incidence and mortality, whether we choose a one or two year year long run-in period. Only exception is for incidence, and this is a result of a high incidence in 1993. With a two year run-in period, we are forced to omit this year when estimating trends, and hence the trend is attenuated.

###### 

Discontinuation of anti-diabetic treatment

         Females   Males                                 
  ------ --------- ------- ----- ----- ----- ----- ----- -----
  1993   198       6.6                 174   5.6         
  1994   209       6.7     118   3.5   185   5.7   99    2.8
  1995   199       6.2     133   3.8   188   5.5   115   3.1
  1996   172       5.3     121   3.5   203   5.8   108   2.9
  1997   188       5.5     101   2.8   196   5.2   113   2.8
  1998   163       4.6     123   3.3   182   4.6   117   2.8
  1999   135       3.7     102   2.7   166   4.0   108   2.5
  2000   150       4.0     92    2.3   194   4.5   97    2.1
  2001   282       7.1     100   2.4   375   8.2   114   2.3
  2002   176       4.2     117   2.6   233   4.8   122   2.4
  2003   189       4.2     99    2.1   250   4.9   126   2.3

Number of patients discontinuing anti-diabetic treatment, Fyn County, Denmark, 1994--2003. Discontinuation is defined as subjects with more than one or two years, respectively, without redemptions after a previous redemption. Percentage figures indicate relative proportion of the prevalent population who discontinues treatment.

If, however, we were to naively use all available information prior to a given index date to determine treatment status, trend estimates of prevalence become markedly increased, and trend estimates for incidence decreased. The relative biases of this naive approach range from 20%--40% for these parameters. Trends in mortality are unaffected by using a variable length run-in period.

Methodological considerations II: Trends in detection proportions
-----------------------------------------------------------------

In Figure [2](#F2){ref-type="fig"} we present the results of our sensitivity analysis. As observed trends in incidence we used the estimated trends of 1.048 (1.03.8, 1.058) for females, and 1.045 (1.035, 1.054) for males. Even for unrealistic large changes in detection proportions the trend in true incidence does not vanish.

![Observed and true trends in incidence with respect to hypothesized changes in detection proportions from 1994 to 2003. Confidence limits for the true trends are computed from the confidence limits of the observed trend by application of Formula 1.](1478-7954-5-2-2){#F2}

Methodological considerations III: Anatomy of an \"epidemic\"
-------------------------------------------------------------

Above we observed an increase in prevalence and incidence accompanied by a decrease in mortality among treated. A common interpretation would be to explain the trend in prevalence with the concurrent trends in incidence and mortality. This would however be an oversimplification if prevalence could rise while incidence and mortality rates remained constant. To examine whether this actually occurred during the study period, we compared the observed number of prevalents over the study period to the number of prevalents that would be predicted if incidence, mortality among treated, and cessation rates all had remained constant at their level in 1994. Alternatively, we only fixed incidence rate at its 1994-level, while allowing mortality among treated and cessation rates to vary as observed. The resulting projections are shown in Figure [3](#F3){ref-type="fig"}.

![Observed and predicted prevalences with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994--2003. Fixation of rates is with respect to their 1994-level.](1478-7954-5-2-3){#F3}

For the period 1995--1999, agreement is very good between observed and projected prevalence among females, while poorer among males. For both genders the discrepancy increases from year 2000. Keeping only incidence fixed improves agreement between observed and projected prevalence substantially, in particular among men, ie. for men the combined decline in mortality and cessation explain more of the observed rise in prevalence than for women. The bulk of the rise in prevalence is thus not due to contemporary changes in incidence or mortality rates, but to incident subjects outnumbering deaths among treated and treatment cessations.

Discussion
==========

Throughout the study period, prevalence of use of anti-diabetic agents increased both in absolute and relative terms, as well as within and across age strata. The corresponding incidence also increased, while mortality among treated declined, also relative to mortality among untreated. This agrees with previous results \[[@B7]\], except with respect to incidence.

The data used are generally of high validity, as they result from automated registration of economic transaction data; near complete coverage, except for medications filled at a pharmacy outside the subjects residential county, which for all drugs was found to not exceed 0.5% \[[@B12]\]; the information on migration and vital statistics is identical to the relevant subset of the registration at Statistics Denmark.

The major limitation of the present study is its reliance on drug redemptions. Obtaining a drug is not equivalent to using it, and when used there is no observation of end of use. Consequently, we investigated the impact of different treatment classification rules and found that trend estimates for prevalence, incidence, and mortality were largely unaffected, except for the flawed principle of using a run-in period of varying length.

Further, our estimates for prevalence, incidence, and mortality by definition only concern subjects with treated diabetes, i.e. our results do not apply to undiagnosed diabetics, nor to diabetics treated exclusively with diet. These subjects are misclassified in the sense that they are considered part of the general, non-diabetic population in the present study. As all Danish citizens are covered by a government funded health care plan, the annual cost of medications for chronic diseases to be paid by a single individual cannot exceed approximately DKK 3,600 (nearly USD 600) per year. In contrast to many other countries one may therefore expect a rather limited dependence of misclassification rates on social class and, in particular, financial capacity. Other heterogeneities in misclassification rates due to life style, attitudes to health care, etc., may also exist, but like those due to financial capacity and social class, we have little reason to assume that they have changed substantially over the last decade and could imply artificial time trends in incidence or prevalence. Especially, we did not identify the age trend in cessation rates reported by Glynn *et al*in two studies \[[@B17],[@B18]\]. Only for the youngest age-groups were cessation rates slightly elevated, and this may indicate that misclassification may not so much depend on cost as on need and perceived necessity of treatment.

The prevalence level of pharmacologically treated diabetes found here is in line with other contemporary studies in Denmark \[[@B19],[@B20]\]. For the year 1996, Kristensen *et al*\[[@B21]\] found that 71% of all patients diagnosed with type II diabetes in Vejle County, Denmark, were treated pharmacologically. Further, Drivsholm *et al*\[[@B19]\] estimated from a one year run-in period the number of pharmacologically treated diabetes patients in Denmark on Dec 31, 1999, to 98,358, constituting about 75% of the population of all identified diabetics, estimated to about 130,000 on the same date. Interestingly, Drivsholm *et al*also found that their primary data sources on hospital discharge diagnosis, measurement of blood glucose, and diabetic foot care, were only able to identify approximately 80%--90% of patients treated pharmacologically for diabetes, indicating the lack of a single data source with complete coverage. In short, it appears reasonable to consider the proportion of pharmacologically treated diabetes patients constant across the study period at about 75%, and to expect the estimated trends in prevalence of pharmacologically treated diabetes to be valid for the entire diabetes population. Regardless, we suggest our results to be of genuine public health interest in themselves, as they pertain to that group of diabetics which must generally be considered most severely afflicted, and thus requiring most care.

A third consequence of relying on a pharmacoepidemiological database is the inability to control for date of diagnosis in the analysis. In particular, in the analysis of mortality among treated we could not account for duration of disease, and part of the explanation for the apparently decreasing mortality could be earlier treatment of patients with less severe diabetes.

The trend in incidence identified in this study was comparable to the one found for the period 1993--1999, reported in \[[@B7]\], although slightly attenuated. The attenuation occurred both because the year 1993 was excluded in the present study using a two year run-in period, and because incidence began a steeper increase in 2000. Combined with the enlarged sample size due to a longer study period, this made the trend statistically significant. The increase in incidence observed after year 2000 could hallmark the onset of a true diabetes epidemic, possibly reflecting an impact from a sustained obesity epidemic on onset of diabetes or other changes in lifestyle -- although postulating a general obesity epidemic in Denmark would also appear to be an over-simplification according to a recent study showing the existence of large heterogeneity in obesity trends \[[@B22]\]. That an epidemic of diabetes could be looming was supported by the finding that fixing incidence at its level in 1994 could predict prevalence with good precision until 2000, at which point the observed prevalence started to outrun projected prevalence. It may, however, be speculated that new diagnostic criteria, which eased detection of new cases and were implemented in 1999 in Denmark, could have contributed to the observed increase in incidence. For trends in incidence, our somewhat simplistic sensitivity analysis did however show that even unrealistically large changes in detection proportions could not remove the observed trend in incidence entirely. One must however interpret these results cautiously for two reasons. First the detection proportions are by definition a simplified representation of the problem, as they ignore the duration between true onset of disease and initiation of pharmacological treatment. We are however not aware of any studies on this duration, let alone trends in durations, which could be used to further qualify our analysis, as existing studies only report prevalence of undiagnosed diabetes \[[@B23]\]. Secondly, the detection proportion covers both diagnosis and treatment initiation. It might well be speculated that a trend towards earlier diagnosis could be offset by a smaller need for pharmacological treatment among those with earlier diagnosis. For this reason we believe that the studied range of changes in detection proportions is probably too wide to only contain realistic values. Note, that our considerations about the relation of observed incidence, prevalence and mortality are independent of any assumptions about the causal reason for a shift in incidence, be it a real increase in subjects developing diabetes, a change in diagnostic procedures, criteria or habits, or a change in treatment practices.

Whatever the explanation, the trend in incidence should not be considered the primary reason for the concurrent increase in prevalence. Instead, the primary explanation is the annual surplus of subjects initiating treatment for diabetes compared to those leaving treatment which must be considered a legacy of past diabetes incidence and treatment. The surplus may be expected to increase further, if current trends in incidence and mortality persist, and projections by WHO and others may thus severely underestimate the true magnitude of diabetes prevalence ten to twenty years from now, built as they are on stationary age-specific incidence and mortality estimates \[[@B3]\].

In conclusion, we suggest that pharmacoepidemiologic databases can provide useful information on current trends in diabetes epidemiology if analyzed properly, and at a much lower cost than ordinary studies. The major drawback is the lack of insight in the underlying reasons for any observed trends -- an insight which can only be obtained on a regular basis if a population-wide case database collecting information on all incident and prevalent diabetes cases is established.
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